Addex Therapeutics reported a significant decrease in sales for Q2, down 71.27% year-over-year, alongside a narrowing of its per-share losses. While the reduced loss per share might appear positive, the substantial revenue decline is a major concern for the company's financial health and future prospects.
Addex Therapeutics (ADXN) disclosed its Q2 earnings, revealing a substantial 71.27% year-over-year decrease in sales, dropping from $44.031 thousand to $12.650 thousand. While the company did manage to reduce its loss per share from $(2.90) to $(1.52), this improvement is overshadowed by the dramatic revenue decline. This filing is highly significant as it indicates a severe operational challenge for the company, potentially impacting its ability to fund ongoing research and development. Traders should note the short-term negative implications for ADXN's stock price due to the poor sales performance, and long-term concerns about the company's growth trajectory and financial viability.